Oculis

This week, Oculis announced the appointment of Daniel S. Char as Chief Legal Officer. Mr. Char brings to Oculis extensive legal expertise in corporate governance, compliance, drug development and commercialization, financing, licensing, and merger and acquisition transactions from working with successful biotech and medical device companies. This appointment further expands Oculis’ leadership team as the company advances its late-stage pipeline and prepares for its commercial phase.

We are honored to announce Dr. Andrea Govetto as the inaugural recipient of the first Ramin Tadayoni Award at this year’s European Society of Retina Specialists (EURETINA) conference. We are very impressed by Dr. Govetto’s pioneering efforts in advancing research and are confident in his ability to drive research excellence and innovation in retinal care. Congratulations, Dr. Govetto! This award, named in recognition of the late, world-renowned retina specialist, Ramin Tadayoni, celebrates his significant contributions to advancing ophthalmic disease research. 

Our CEO, Riad SHERIF, M.D, is heading to Barcelona this week as he will be presenting at the 2024 European at Ophthalmology Futures Forums on September 5. Join us as he shares more details on our latest pipeline advancements including the recent topline data with OCS-02 (Licaminlimab) from the RELIEF Phase 2b trial. Learn more about our recent progress in our Q2 Earnings press release here #EyeHealth #Ophthalmology #BioTech #BioPharma #EyeDisease #OphthalmologyFuturesForums2024 

We are excited to share our upcoming investor conferences participation in September 2024, including the Wells Fargo Healthcare, H.C. Wainwright & Co., LLC, and Baird conferences.   It will be great opportunities for the Oculis team to share recent advances with all clinical candidates including the ongoing OCS-01 Phase 3 DIAMOND trials in DME, the recently announced OCS-02 (licaminlimab) Phase 2b results in DED, and OCS-05, our novel neuroprotective product candidate, with upcoming topline readout in acute optic neuritis anticipated in Q4 2024! Learn more about our ongoing pipeline developments here: https://lnkd.in/eDPn5MQc.    #EyeHealth #Ophthalmology #BioTech #BioPharma #EyeDisease #HCWainwright #Baird #WF

We are thrilled to announce the appointment of Sharon Klier, M.D., M.S., M.P.H. as Oculis’ Chief Development Officer. In this key role, Dr. Klier will oversee and provide strategic leadership across the clinical development and operations of Oculis’ #pipeline, drawing on over 20 years’ experience across #ophthalmology and other therapeutics areas.   With the ongoing DIAMOND-1 and DIAMOND-2 Phase 3 trials with OCS-01 in DME, Dr. Klier’s breadth of knowledge in ophthalmic clinical development and regulatory approvals will be crucial as we advance our late-stage #pipeline and further expand our R&D team and U.S. presence.   For additional details on this announcement, including important information on forward-looking statements, see our press release here: https://bit.ly/4cn8ppz     #Appointment #NewHire #Biotech #EyeHealth

This week, Riad SHERIF, M.D., Chief Executive Officer of Oculis will participate in the “Derisked Late-stage Candidates for Retinal Disorder” panel discussion at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference.   Oculis is committed to driving forward it’s late-stage clinical development programs to save sight and improve eye care including both Phase 3 DIAMOND trials with OCS-01 eye drops for diabetic macular edema.   For additional details on our participation, see our press release here: https://bit.ly/3WMXZuR   The Panel is scheduled for August 15, 2024 at 11:00 am ET and a corporate presentation of Oculis will also be made available, on demand, on August 15, 2024 at 7:00am ET.   To access both webcast links, please visit: https://lnkd.in/eKgVER_5   #eyehealth #opthalmology #biotech #biopharma #eyedisease #HCWainwright

Happy Swiss National Day!   Today, we have double the reasons to celebrate! Not only are we honoring the rich history and vibrant culture of Switzerland, but we are also thrilled to announce the grand opening of Oculis' new office in the beautiful city of Lausanne!   With significant growth across both our US and Swiss teams, our new office in Lausanne represents a significant milestone for us, supporting our highly differentiated #pipeline of innovative products that have the potential to save sight and improve #EyeCare globally. This includes OCS-05, a novel serum-glucose corticoid kinase-2 (SGK-2) activator that is currently being evaluated in our Phase 2 ACUITY trial for the treatment of Acute Optic Neuritis (AON). Currently, there are no specific therapy approved for AON, a rare disease which is characterized by an acute inflammation of the optic nerve that can lead to permanent visual impairment. The ACUITY trial is set to read out before the end of the year.   For additional details on the ACUITY trial including important information on forward-looking statements, please visit: https://bit.ly/3wzw336   Here’s to continuous growth and bright futures from our new base in Lausanne!   #SwissNationalDay #Oculis #Ophthalmology #Innovation #EyeHealth #Biotech

Dry Eye Awareness Month highlights this prevalent disease affecting nearly 40 million people in the United States alone and can lead to ocular discomfort, fatigue, and visual disturbances, significantly impacting their quality of life. A recent report showed that the vast majority of patients (87%) don’t feel that their chronic dry eye disease is well-managed with current treatment options. As a company focused on saving sight and improving eye care, we are committed to advancing innovative treatments for diseases such as DED. To learn more, check out this recent Q&A in @Healio with Riad SHERIF, MD, our CEO, and Dr. Anat Galor, Professor of Ophthalmology at the Bascom Palmer Eye Institute, University of Miami, discussing the recent positive topline results from the phase 2b RELIEF trial with licaminlimab, Oculis’ novel anti-TNF-α eye drop, and highlighting the Company’s #PrecisionMedicine approach that has the potential to transform the current treatment paradigm for DED: https://lnkd.in/evsRQXMJ   #Ophthalmology #DryEyeAwarenessMonth #DryEye #EyeHealth #Biotech

EURETINA and Oculis have come together to pay a lasting tribute to Professor Tadayoni’s legacy. In this effort, EURETINA has established the Ramin Tadayoni Award supported by Oculis. Professor Tadayoni was a world-renowned retina specialist who contributed greatly to the field of ophthalmology and to Oculis’ success as Retina Chair of the company’s Scientific Advisory Board and as Chief Scientific Officer, at the time of his unexpected passing earlier this year. Throughout his career, Professor Tadayoni was highly committed to advancing retinal research and education. This annual award will combine both of these profound values by supporting the next generation of talented ophthalmologists who have demonstrated outstanding potential in retinal research and are driving forward innovation in the field. For additional details on this announcement, see our press release here: https://bit.ly/4ezIZY9 For more information about the Ramin Tadayoni Award, including eligibility requirements and how to apply, visit: https://lnkd.in/eFgZen6f #eyehealth #ophthalmology #biotech #biopharma #eyedisease #education #researchgrant

Following our recent Phase 2 RELIEF data for licaminlimab (also known as OCS-02), our novel anti-TNFα antibody eye drop candidate, the Oculis team had the opportunity to attend the 2024 @European Dry Eye Society Congress (#EuDEC 2024). We enjoyed the opportunity to discuss the data, which delivered further evidence to support the potential of our #PrecisionMedicine approach for the treatment of dry eye disease (#DED), a growing area of unmet need that affects nearly 40 million people in the US alone.   The RELIEF trial was an exploratory study designed to achieve three specific objectives: to evaluate the efficacy of licaminlimab on the signs of DED, to confirm the TNFR1 genetic biomarker as a predictor of response and to select the primary sign efficacy endpoint for a future Phase 3 trial. The trial met all three of these objectives, with positive topline data complementing two prior successful Phase 2 studies, during which the TNFR1 genetic biomarker was identified as a predictor of high responders to therapy. Excitingly, improvement of multiple signs of DED were observed in the full trial population, with more pronounced effect in the subpopulation with a TNFR1-related genotype, consistent with earlier trial results and laying the groundwork for progression towards a Phase 3 study.   For more information on the RELIEF topline results including important information on forward-looking statements, see our press release here: ur press release here: https://bit.ly/4bWdQw0